Aptose Biosciences Inc. (NASDAQ:APTO) CEO William G. Rice Buys 100,000 Shares

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average cost of $0.20 per share, with a total value of $20,000.00. Following the transaction, the chief executive officer now owns 613,252 shares in the company, valued at approximately $122,650.40. This represents a 19.48 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Aptose Biosciences Price Performance

Shares of Aptose Biosciences stock opened at $0.18 on Thursday. The business has a 50-day moving average of $0.36 and a 200-day moving average of $0.58. The company has a market capitalization of $3.24 million, a PE ratio of -0.06 and a beta of 1.26. Aptose Biosciences Inc. has a 1-year low of $0.13 and a 1-year high of $2.91.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on APTO. StockNews.com began coverage on shares of Aptose Biosciences in a research report on Thursday, November 21st. They issued a “hold” rating for the company. HC Wainwright decreased their price target on Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, November 20th.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.